Previous studies have demonstrated that targeting the integrin β3/FAK signaling could enhance the anti-tumor activity and attenuate cancer metastasis in melanoma, endometrial cancer, NSCLC, and ESCC [34–36]. Here, PTK2 is linked to neoplasm.